CRISPR Therapeutics AG
NASDAQ: CRSP
$65.35
+$0.86 (+1.3%)
Closing price September 30, 2022
Barclays recently issued a few calls across multiple industries picking a couple winners and a couple losers.
1 month ago
Tuesday's additional top analyst upgrades and downgrades were on Bed Bath & Beyond, Clorox, CRISPR Therapeutics, LivePerson, Nike, Palantir Technologies, Tyson Foods and more.
1 month ago
One big Wall Street name thinks it has found a big winner in this gene-editing company, and the stock could benefit greatly going forward.
3 months ago
Thursday's additional top analyst upgrades and downgrades included American Tower, Coinbase, Snowflake, Southwest and more.
3 months ago
Wednesday's top analyst upgrades and downgrades included Albemarle, Camping World, eBay, EOG Resources, Etsy, Global Payments, IMAX, JPMorgan Chase, MetLife, Otis Worldwide, Salesforce, Wayfair and...
4 months ago
Last Updated: 4 months ago
Thursday's top analyst upgrades and downgrades included Alcon, Array Technologies, AZEK, Boeing, Capital One Financial, Coinbase Global, Corning, Electronic Arts, Harley-Davidson, ON Semiconductor,...
4 months ago
Last Updated: 4 months ago
Thursday's top analyst upgrades and downgrades included Airbnb, Alcoa, Beyond Meat, Fidelity National Information Services, Marriott International, Monster Beverage, Paramount Global, Shopify, Spirit...
7 months ago
Last Updated: 7 months ago
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...
8 months ago
A couple of Cathie Wood's ARK Invest exchange-traded funds bought nearly 60,000 shares of CRISPR Therapeutics on December 29 for $4.6 million.
9 months ago
Tuesday afternoon's top analyst upgrades and downgrades included Alibaba, Apple, AstraZeneca, Canopy Growth, CNX Resources, Murphy Oil, Ross Stores and Tesla.
9 months ago
Tuesday afternoon's analyst upgrades and downgrades included CRISPR, Editas, Esperion Therapeutics, Marriott Penn National Gaming and more.
11 months ago
A couple of Cathie Wood's ARK Invest exchange-traded funds bought over 675,000 shares of CRISPR Therapeutics on October 14.
11 months ago
A couple of Cathie Wood's ARK Invest exchange-traded funds bought over 400,000 shares of CRISPR Therapeutics on October 10.
11 months ago
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
1 year ago
The WallStreetBets community has been a resounding force in the market since January causing many investors to reevaluate their positions. Here's a look going into this trading session.
1 year ago